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Abstract 
Background: Accumulating evidence suggests the origin of Juvenile Myelomonocytic Leukemia 
(JMML) is closely associated with fetal development. Nevertheless, the contribution of 
embryonic progenitors to JMML pathogenesis remains unexplored. We hypothesized that 
expression of JMML-initiating PTPN11 mutations in HSC-independent yolk sac erythromyeloid 
progenitors (YS EMPs) would result in a mouse model of pediatric myeloproliferative neoplasm 
(MPN). 
  
Results: E9.5 YS EMPs from VavCre+;PTPN11D61Y embryos demonstrated growth 
hypersensitivity to GM-CSF and hyperactive RAS-ERK signaling. Mutant EMPs engrafted the 
spleens of neonatal recipients, but did not cause disease. To assess MPN development during 
unperturbed hematopoiesis we generated CSF1R-MCM+;PTPN11E76K;ROSAYFP mice in which 
oncogene expression was restricted to EMPs. YFP+ progeny of mutant EMPs persisted in 
tissues one year after birth and demonstrated hyperactive RAS-ERK signaling. Nevertheless, 
these mice had normal survival and did not demonstrate features of MPN.  
 
Conclusions: YS EMPs expressing mutant PTPN11 demonstrate functional and molecular 
features of JMML but do not cause disease following transplantation nor following unperturbed 
development.  
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 Introduction 
Juvenile Myelomonocytic Leukemia (JMML) is a pediatric myeloproliferative neoplasm 
(MPN) caused by mutations in RAS-ERK signaling genes. Gain of function PTPN11 mutations 
are the most frequent cause of JMML, and are present in ~35% of cases (Sakaguchi et al., 
2013; Caye et al., 2015; Stieglitz et al., 2015). Patients suffer from monocytosis, anemia, 
thrombocytopenia, hepatosplenomegaly, and have a poor overall survival (Chan et al., 2009b; 
Locatelli and Niemeyer, 2015). Recent evidence has implicated a developmental origin to this 
disease. Children present very young with a median age of <2 years. Patients frequently have 
elevated levels of fetal hemoglobin and their bone marrow cells have a gene expression 
signature characteristic of fetal progenitors (Weinberg et al., 1990; Helsmoortel et al., 2016). 
Furthermore, retrospective analysis suggests that the majority of somatic JMML-initiating 
mutations occur before birth (Kratz et al., 2005; Matsuda et al., 2010; Stieglitz et al., 2015). 
Nevertheless, the identity of the JMML-initiating cell remains controversial. 
The first murine hematopoietic stem cell (HSC) emerges around E11.0 in the aorta-
gonad-mesonephros region (Muller et al., 1994; Boisset et al., 2010). The HSC migrates to the 
fetal liver, expands, and seeds the bone marrow around birth (Christensen et al., 2004). The 
emergence of HSCs is preceded by sequential waves of hematopoiesis that originate in the 
extraembryonic yolk sac (YS) and consist primarily but not exclusively of progenitors with limited 
differentiation and self-renewal potential (Frame et al., 2013; Lin et al., 2014). The first HSC-
independent wave consists of bipotent megakaryocytic-erythroid progenitors (MEP) and 
myeloid-restricted progenitors (Mac-CFC) (Moore and Metcalf, 1969; Bertrand et al., 2005; 
Tober et al., 2007). These arise directly from mesoderm around E7.0 and are termed primitive 
due to their morphology. A second HSC-independent wave begins around E8.25 with the 
emergence of erythromyeloid-progenitors (EMPs) via an endothelial-to-hematopoietic transition 
(Palis et al., 1999; Lux et al., 2008; Frame et al., 2016). EMPs seed the fetal liver around E10.5 
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where they give rise to enucleated erythrocytes and diverse myeloid progeny including 
neutrophils, monocytes, and macrophages (Chen et al., 2011; McGrath et al., 2015). Following 
EMPs, lymphoid restricted progenitors and multilineage neonatal repopulating cells emerge in 
the YS prior to the first HSC (Yoder et al., 1997; Yoshimoto et al., 2010; Yoshimoto et al., 2012). 
Recent evidence has highlighted the importance of EMPs in development. EMPs are 
integral for in utero vascular remodeling and sterile inflammatory signals from EMP-derived 
myeloid progeny promote the emergence of HSCs (DeFalco et al., 2014; Espin-Palazon et al., 
2014; Li et al., 2014; Kasaai et al., 2017). Furthermore, loss of EMPs is not compatible with life 
since their progeny are required to sustain the embryo during the late fetal period when HSC-
dependent progenitors are proliferating (Mucenski et al., 1991). Finally, whereas initial studies 
suggested EMPs had a transient role in development, recent work has proven that the progeny 
of EMPs persist into adulthood as tissue resident macrophages (Samokhvalov et al., 2007; 
Ginhoux et al., 2010; Schulz et al., 2012; Kierdorf et al., 2013; Epelman et al., 2014; Gomez 
Perdiguero et al., 2015; Hoeffel et al., 2015). YS-derived macrophages are present in the 
majority of organs at birth, and undergo gradual replacement by HSC-derived progeny. The rate 
of this replacement varies by tissue; it is very rapid in the gut, whereas it is delayed in the 
spleen, liver, and heart. Importantly, there is negligible replacement of brain YS-derived 
macrophages. The majority of microglia retain an embryonic origin life-long, even after HSC 
transplant (HSCT) (Kennedy and Abkowitz, 1997; Ginhoux et al., 2010; Hashimoto et al., 2013). 
The contribution of YS progenitors to JMML is unknown. Several lines of evidence—in 
addition to the disease’s in utero origin and fetal characteristics—suggest that EMPs may 
contribute to the pathogenesis of this disease. JMML has been successfully modelled with 
patient-derived induced pluripotent stem cells (iPSCs) (Gandre-Babbe et al., 2013; Mulero-
Navarro et al., 2015). However, iPSCs cannot give rise to HSCs and can only recapitulate YS-
like HSC-independent hematopoiesis (Vanhee et al., 2015; Buchrieser et al., 2017). This 
suggests that YS-derived progeny will have defining features of JMML. Additionally, whereas 
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HSCT is the only curative treatment for JMML, up to 52% of patients will relapse (Locatelli et al., 
2005; Olk-Batz et al., 2011) suggesting that malignant JMML cells are uniquely resistant to 
myeloablation. Since tissue resident macrophages in both mice and humans are also relatively 
resistant to myeloablation, we hypothesized that EMPs may contribute to JMML relapse via their 
long-lived myeloid progeny (Kennedy and Abkowitz, 1997; Haniffa et al., 2009; Hashimoto et al., 
2013).  
Previous studies have struggled to identify the contribution of YS progenitors to disease. 
One study used transplantation experiments to evaluate the HSC-dependent vs. HSC-
independent origin of tumor-associated macrophages (Gordon et al., 2017). However, 
transplantation is not a reliable approach since YS-derived macrophages outside the brain are 
gradually replaced by donor contributions – albeit at a slower rate than HSC-derived myeloid 
populations. Other studies have assessed the aberrant function of mutation-expressing YS 
progenitors ex vivo and have shown them to have unique disease phenotypes. For instance, 
YS-derived megakaryocytes are uniquely hyperproliferative following expression of truncated 
GATA1 (Li et al., 2005). However, this study was not able to assess the postnatal 
consequences of mutations restricted to YS progenitors.  
In our study, we use complementary approaches to evaluate the consequences of 
JMML-associated gain-of-function PTPN11 mutations in EMPs. In addition to ex vivo assays 
and transplantation experiments, we take advantage of inducible lineage tracing Cre-loxP 
techniques to study the postnatal effects of mutant EMPs. We thereby definitively address our 
hypothesis that restricted expression of mutant PTPN11 in YS EMPs will be sufficient for the 
emergence of MPN in a mouse model of JMML. We demonstrate that YS EMPs expressing 
gain-of-function PTPN11 have defining features of JMML, including growth hypersensitivity to 
GM-CSF and RAS-ERK hyperactivation. Nevertheless, mutant YS EMPs were not able to give 
rise to MPN following transplantation nor following unperturbed development despite the 
durable persistence of their progeny in adult mice.  
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Results 
We hypothesized that in utero expression of the PTPN11D61Y JMML-initiating mutation 
would result in the rapid onset of MPN in mice. To test this hypothesis we activated the 
oncogene in early hematopoietic progenitors using VavCre, whose expression begins in fetal 
blood cells (Ghiaur et al., 2008). VavCre+; PTPN11D61Y mice were viable and born at expected 
Mendelian ratio (Fig-1A), developed leukocytosis and monocytosis by 8 weeks of age, and had 
a median survival of 31 weeks (Fig-1B). Given that Mx1Cre+;PTPN11D61Y mice have a reported 
median survival of 45 weeks, our results suggest that oncogene expression by in utero 
progenitors exacerbates progression of PTPN11D61Y-induced MPN (Chan et al., 2009a).  
To confirm that embryonic progenitors expressing PTPN11D61Y manifested features of 
MPN, we assayed their growth in methylcellulose medium with increasing doses of GM-CSF. 
Both E14.5 fetal liver (FL) progenitors and E9.5 YS progenitors from VavCre+;PTPN11D61Y 
mutant embryos had markedly greater colony formation at low doses of GM-CSF compared to 
littermate controls (Fig-1C,D). To evaluate if this GM-CSF hypersensitivity was due to 
hyperactive RAS signaling, we measured the phosphorylation (p-) of ERK. Mutant cells cultured 
from E14.5 FL had markedly elevated p-ERK levels both at baseline and following 30min 
stimulation with 10ng/ml GM-CSF, as measured by western blot (Fig-1E). Additionally, mutant 
cells cultured from E9.5 YS also had elevated p-ERK and p-STAT5 levels as measured by 
intracellular flow cytometry (Fig-1F). These results demonstrate that both HSC-dependent FL 
progenitors and HSC-independent YS cells have defining functional features of JMML. To 
determine the identity of the hyperactive YS progenitor, we sorted Ter119- CD41dim cKit+ YS 
EMPs from E9.5 VavCre+;PTPN11D61Y mutants and littermate controls. Mutant EMPs produced 
greater numbers of colonies at the tested concentrations of GM-CSF (Fig-1G), providing 
evidence that the EMP is the YS progenitor responsible for the observed features of JMML. 
Tissue macrophages are the durable progeny of EMPs and they are relatively resistant 
to myeloablation compared to other myeloid cells. As such, mutant EMPs may contribute to 
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JMML relapse following HSCT via their myeloablation-resistant progeny. To test this notion, we 
devised a therapeutic HSCT in which VavCre+;PTPN11D61Y mice were treated with adoptive 
transfer of healthy CD45.1+ BM cells (Fig-2A). We hypothesized that recipients would relapse 
following poor donor engraftment. We transplanted 12-24week old lethally irradiated mutant and 
littermate animals (CD45.2+) with 5x105 heathy congenic CD45.1+ BM cells. We were surprised 
to observe that donor cells engrafted more readily in mutant recipients than in control recipients 
(Fig-2B). Furthermore, the engrafted cells preferentially gave rise to CD11b+ myeloid cells and 
to fewer CD3+ T-lymphocytes (Fig-2C). Despite this robust engraftment, mutant recipient mice 
rapidly succumbed after transplantation, with a mean survival of 16 weeks (Fig-2D). To evaluate 
whether limiting donor cell numbers affected post-transplant survival, we repeated the 
experiment using 1x107 CD45.1+ donor BM cells. Mutant mice nevertheless succumbed with a 
median survival of 18 weeks (Fig-2D). 
At analysis, moribund mutant recipients had a hypercellular BM with an effacement of 
the normal splenic follicular architecture (Fig-2F,G). We were surprised, however, to find 
markedly enlarged thymuses in moribund mutants (not shown). Subsequent analysis confirmed 
that both the BM and spleen were filled with CD45.2+ recipient-derived CD4+ CD8+ cells, which 
are indicative of T-cell leukemia/lymphoma (T-ALL) (Fig-2E). Transplantations of BM and spleen 
cells from HSCT-treated mutants into CD45.1 recipients confirmed that the CD45.2+ T-ALL 
disease could be propagated and was neoplastic (not shown). From these experiments we 
concluded that healthy donor cells could efficiently engraft mutant recipients and preferentially 
gave rise to myeloid progeny. Despite this robust engraftment, mutants died after 
transplantation due to the emergence of a recipient-derived T-ALL, which could be propagated 
upon transplantation. Importantly, this finding contrasts with JMML patients who rarely 
demonstrate emergence of T-ALL and primarily relapse with MPN following HSCT (Cooper et 
al., 2000). 
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PTPN11D61Y murine models have indolent disease progression. We reasoned that a 
different JMML-associated PTPN11 mutation that causes more rapid disease onset would help 
accentuate our findings. We chose the conditional PTPN11E76K mouse because it succumbs to 
MPN more rapidly than PTPN11D61Y mice and because this mutation has been documented to 
occur in utero in JMML patients (Matsuda et al., 2010; Xu et al., 2011).  
Sorted YS EMPs from E10.0 VavCre+;PTPN11E76K were growth hypersensitive to GM-
CSF, further demonstrating that mutated HSC-independent progenitors have features of JMML 
(Fig-3A). Surprisingly, when we mated VavCre mice with PTPN11E76K/+ mice we did not obtain 
viable VavCre+;PTPN11E76K progeny (Fig-3C). Analyses of E10.5 embryos showed mutants 
were smaller, less developed, and had a pale YS and AGM region (Fig-3D). Subsequent 
analysis of E17.5 embryos confirmed that VavCre+;PTPN11E76K embryos were dying in utero 
(Fig-3D). This was in contrast to recent publications that reported this model to be viable and 
develop MPN (Dong et al., 2016; Liu et al., 2016). This discrepancy is likely due to the use of 
different VavCre strains. Prior studies used the VavCreStadtfeld strain, which has minimal 
expression in endothelial and stromal cells. In contrast, the VavCreCroker and VavCredeBoer strains 
in our studies have pronounced expression in endothelial cells which may cause the prenatal 
lethality we observed (de Boer et al., 2003; Croker et al., 2004; Stadtfeld et al., 2007).  
Despite the in utero lethality of VavCreCroker;PTPN11E76K mice, their E10.0 YS 
hematopoietic progenitors gave rise to a normal distribution of BFU-E, CFU-GM, and CFU-
GEMM colonies (Fig-3B). We therefore tested whether YS progenitors could give rise to MPN 
upon transplantation. We transplanted 1 embryo equivalent (e.e.) FACS-sorted YS EMPs from 
E10.5 VavCre+;PTPN11E76K embryos i.v. into 150cGy sublethally irradiated neonatal NSG 
CD45.1+ recipients. We also transplanted CD45- Ter119- cKit+ VE-Cadherin+ hemogenic 
endothelial populations from the AGM of the same embryos (Rybtsov et al., 2011). Prior work 
has demonstrated neonatal recipients are uniquely capable of supporting YS progenitor 
engraftment (Yoder and Hiatt, 1997; Yoder et al., 1997; Yoshimoto et al., 2010; Yoshimoto et 
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al., 2012; Arora et al., 2014). Nonetheless, we did not observe peripheral blood engraftment or 
elevated leukocyte counts in recipients of either YS or AGM cells (Fig-3E). This finding is 
consistent with recent studies that showed purified YS EMPs did not contribute to circulating 
leukocytes following transplantation (McGrath et al., 2015).  
At tissue analysis 18 weeks post-transplant, we were surprised to discover that donor 
EMPs had engrafted in recipient spleens as F4/80+ CD11bdim macrophages (Fig-3F). The 
engraftment of splenic macrophages was more robust in recipients of YS EMPs than of AGM 
VECad+ cells. Notably, whereas the most prominent progeny of EMPs are microglia, we did not 
detect any CD45.2+ cells in the brains of EMP recipients (Fig-3G). These results are consistent 
with previous studies that showed differences in progenitor differentiation under native and 
transplant settings (Boyer et al., 2011; Busch et al., 2015). Our findings highlight the pitfalls of 
models that rely on transplantation, which identify progenitor potentials under non-native 
conditions (Schlenner and Rodewald, 2010; Busch and Rodewald, 2016). We concluded that it 
would not be feasible to definitively evaluate the contribution of HSC-independent progenitors to 
JMML using the VavCre model. 
We therefore turned to the CSF1R Mer-Cre-MER (MCM) model which can restrict Cre 
activity to YS EMPs following 4-hydroxytamoxifen (4OHT) injection of pregnant dams at E8.5 
(Qian et al., 2011; Gomez Perdiguero et al., 2015). We mated CSF1R-MCM+;ROSAYFP/YFP studs 
with PTPN11E76K/+ dams to generate mutant CSF1R-MCM;ROSAYFP/+;PTPN11E76K/+ progeny 
(CSF1R-MCM;PTPN11E76K) (Fig-4A). In these animals, Cre-mediated recombination results in 
the expression of both PTPN11E76K and yellow fluorescent protein (YFP). As such, cells 
expressing the oncogene can be monitored using flow cytometry. 24 hours after oncogene 
activation by 4OHT injection, mutant and littermate embryos had equal frequencies of YS EMPs 
(Fig-4B). Additionally, the frequency of YFP+ EMPs was equivalent in both mutants and 
controls. (Fig-4C). This indicated that mutants and littermates had equivalent activity of the Cre 
recombinase. We proceeded to assess proliferation of EMPs using Ki67 staining. EMPs from 
Page 9 of 35
John Wiley & Sons, Inc.
Developmental Dynamics
D
ev
el
op
m
en
ta
l D
yn
am
ic
s
mutant YS did not have increased Ki67 expression compared to their littermates (Fig-4D). 
Additionally, p-ERK levels in both YFP+ and YFP- EMPs from mutant embryos was not 
increased following GM-CSF stimulation compared to control EMPs (Fig-4E).  The lack of cell 
cycle and signaling differences may be attributed to the highly proliferative nature of embryonic 
hematopoietic progenitors as compared with their adult counterparts (Bowie et al., 2007). We 
reasoned that any oncogenic effects of PTPN11E76K mutation would only be evident postnatally, 
once hematopoietic progenitors enter a state of relative quiescence. 
We proceeded to generate a cohort of CSF1R-MCM; PTPN11E76K animals that had been 
exposed to 4OHT at E8.5 (Figure-5A). Mutants were weaned at a normal Mendelian frequency 
of 24% and were physically indistinguishable from littermates (Fig-5B).  We monitored all 
animals in this cohort with monthly peripheral blood draws (Fig-5C-G). As expected, we did not 
observe YFP+ cells in the peripheral blood, indicating that Cre was not active in HSCs. Over a 
52 week period, we did not observe leukocytosis, anemia, or thrombocytopenia in mutant 
animals. Furthermore, we did not see evidence of myeloproliferation or skewing of leukocyte 
lineages. Over the course of the study, one mutant animal succumbed from an unclear cause 
and one littermate control succumbed to sporadic T-ALL (Fig-5H). 
We considered that indolent MPN progression in these animals may not manifest in the 
peripheral blood and would only be evident upon tissue examination. We hypothesized that 
mutant adults would have a greater frequency of YFP+ macrophages compared to controls due 
to growth promoting effects of PTPN11E76K. However, upon analysis, mutant animals did not 
have hepatosplenomegaly and no YFP+ cells were detected in the BM and spleen (Fig-6A,B). 
Additionally, mutant animals had a normal distribution of leukocyte lineages in the BM and 
spleen, indicating absence of myeloid-biased differentiation. (Fig-6C,D).  
We proceeded to characterize macrophage populations in the brain, heart, and liver; the 
tissues with the greatest contribution from YS EMPs. Consistent with previous reports we saw 
high proportions of YFP+ microglia and measureable proportions of YFP+ heart and liver 
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macrophages (F4/80bright CD11b+) (Fig-6E,F). Nonetheless, we did not observe differences in 
the frequency of YFP+ macrophages between CSF1R-MCM; PTPN11E76K and controls in any 
tissue. To determine whether the former presence of mutant splenic macrophages had evoked 
GM-CSF hypersensitivity in progenitors we performed colony forming assays. No difference in 
colony formation was observed between mutant and littermate samples (Fig-6G). To ensure that 
the PTPN11E76K allele was appropriately recombined, we confirmed the excision of the loxP-
STOP-loxP cassette in brains of mutant animals (Fig-6H). We then assayed RAS-ERK signaling 
in freshly-isolated mutant and control microglia and confirmed that mutant cells had greater p-
ERK levels (Fig-6J). These results suggest that in utero PTPN11E76K expression by YS EMPs 
gives rise to tissue macrophage populations with hyperactive RAS-ERK signaling that persist 
more than a year after birth. Nevertheless, these mutant EMPs did not cause overt signs of 
MPN such as monocytosis, anemia, and hepatosplenomegaly. 
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Discussion 
We present the first study to directly assess the contribution of HSC-independent 
hematopoietic progenitors to pediatric neoplasms. We show that YS EMPs expressing mutant 
PTPN11 are hypersensitive to GM-CSF and have hyperactive RAS-ERK signaling. 
Nevertheless, EMPs expressing gain-of-function PTPN11 do not cause disease upon 
transplantation nor following in utero expression using the tamoxifen-inducible CSF1R-MCM 
system. 
Recent studies have provided tantalizing evidence for the potential contribution of 
embryonic HSC-independent hematopoiesis to JMML. The strikingly high relapse rate following 
HSCT suggests that myeloablation-resistant and HSC-independent populations contribute to 
disease emergence (Locatelli et al., 2013). YS EMPs admirably match these criteria: they give 
rise to tissue macrophage populations in diverse tissues that are long-lived and relatively 
resistant to myeloablation (Haniffa et al., 2009; Hashimoto et al., 2013; Epelman et al., 2014; 
Gomez Perdiguero et al., 2015). Second, JMML patients frequently acquire their disease-
initiating mutations in utero (Matsuda et al., 2010; Stieglitz et al., 2015). Finally, several studies 
have successfully modelled JMML using patient-derived iPSCs, whose differentiation mimics 
that of HSC-independent YS hematopoiesis (Gandre-Babbe et al., 2013; Mulero-Navarro et al., 
2015; Vanhee et al., 2015; Buchrieser et al., 2017). This reasoning prompted us to hypothesize 
that expression of JMML-initiating mutations in embryonic HSC-independent progenitors would 
be sufficient for disease development (Chan and Yoder, 2013). 
Our initial experiments with VavCre+;PTPN11D61Y mice demonstrated the feasibility of 
this hypothesis. These animals rapidly succumbed to MPN and their HSC-independent YS 
EMPs had two disease-defining features of JMML: growth hypersensitivity to GM-CSF and 
hyperactive RAS-ERK signaling. This suggested that YS progenitors may contribute to MPN 
emergence. However, transplantation of VavCre+;PTPN11E76K EMPs did not cause disease in 
neonatal NSG recipients despite robust engraftment as splenic macrophages. The inability of 
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mutant macrophages to cause disease further demonstrates that the aberrant peripheral 
monocytes in MPN are distinct from tissue macrophages. This finding is consistent with a 
growing literature that highlights functional, morphologic, and transcriptional differences 
between circulating and resident myeloid cells (Lavin et al., 2014). Importantly, ours is the first 
study to demonstrate durable engraftment of EMPs following transplantation. Previous studies 
showed that transplantation of EMPs into adult recipients resulted in transient erythroid 
contributions but not leukocyte engraftment (McGrath et al., 2015). It is unclear, however, 
whether our engraftment was the result of oncogene-expressing EMPs or whether it was 
enabled by the use of neonatal recipients. Future studies will need to evaluate whether mutant 
PTPN11 or recipient age is the major determining factor permitting EMP engraftment. 
Our study further highlights the challenges of transplantation experiments in studying 
disease initiating cells. The dominant progeny of EMPs in unperturbed hematopoiesis are 
microglia. Nevertheless, we observed EMP engraftment in the spleen but not the CNS following 
neonatal transplantation. Differences between in vivo differentiation and transplantation-evoked 
potentials among adult hematopoietic progenitors have also been shown (Schlenner and 
Rodewald, 2010; Busch and Rodewald, 2016). Additionally, we saw that VavCre+;PTPN11D61Y 
mice engrafted with healthy donor cells had disease exacerbation and rapidly succumbed to 
recipient-derived T-ALL. In contrast, non-irradiated animals expressing PTPN11D61Y die from 
MPN (Chan et al., 2009a). Our findings are consistent with other studies that showed frequent 
T-ALL emergence in irradiated mutant PTPN11-expressing animals due to impaired DNA repair 
(Liu et al., 2016). As such, our results emphasize that the same mutation may give rise to 
divergent disease manifestations in irradiated and non-irradiated animals. 
Previous studies have implicated an abnormal hematopoietic microenvironment in the 
pathogenesis of JMML (Xu et al., 2013; Dong et al., 2016). This group demonstrated that non-
mutated progenitors that occupy a mutant PTPN11-expressing niche have features of MPN 
including hyperactive RAS-ERK signaling and myeloid-biased differentiation. Our finding that 
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healthy donor progenitors preferentially contribute to CD11b+ myeloid cells following 
transplantation into VavCre+;PTPN11D61Y animals is consistent with these earlier findings. 
Additionally, we show that disease reemergence in mutant animals following healthy donor 
HSCT is not caused by impaired engraftment. Rather, the greater frequency of CD45.1+ 
leukocytes in VavCre+;PTPN11D61Y recipients compared to controls suggests that that the 
mutant niche may evoke increased cycling among donor progenitors, potentially leading to 
premature exhaustion. 
Our ex vivo analyses and transplantation experiments demonstrate the challenges of 
measuring the contribution of HSC-independent progenitors to disease. Previous studies also 
relied on transplantation experiments and/or isolation of in utero progenitors (Li et al., 2005; 
Gordon et al., 2017). However, these approaches prevent the analysis of postnatal effects of 
prenatal mutations. Our major advance was to adapt the lineage-tracing CSF1R-MCM system 
to restrict the expression of PTPN11E76K to EMPs and permit the normal birth and development 
of these mice. The concomitant use of the ROSAYFP reporter enabled us to analyze the 
frequency and functional characteristics of mutant EMP progeny. We were thus able to show 
that mutant EMPs in CSF1R-MCM+;PTPN11E76K embryos did not have enhanced proliferation 
or hyperactive RAS-ERK signaling compared to littermates. After birth, no YFP+ EMP progeny 
were observed in the peripheral blood and no evidence of MPN was detected during year-long 
monitoring despite the persistence of YFP+ mutant macrophages in the brain, liver, and heart. 
Microglia in mutants had recombined their PTPN11E76K locus and had hyperactive RAS-ERK 
signaling. Nevertheless, these animals did not have diminished survival and they did not show 
signs of morbidity. 
 There are several possible explanations for the lack of disease in our cohorts. First, YS 
EMPs may not possess the differentiation potential required for fulminant MPN emergence. 
Indeed, whereas EMPs do give rise to neutrophils and monocytes, their long lived progeny are 
tissue resident macrophages, which are functionally, transcriptionally, and epigenetically distinct 
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from the circulating myeloid populations that are expanded in JMML patients (Gosselin et al., 
2014; Lavin et al., 2014). Additionally, healthy EMPs may already be so proliferative that 
PTPN11E76K had no effect on their cell cycle, as measured by Ki67. Furthermore, only 35% of 
E9.5 EMPs were targeted in our model. This is a much lower frequency than the >90% 
efficiency obtained from most conditional mouse models, such as Mx1Cre or VavCre. Finally, 
the CSF1R-MCM can only label EMPs between E8.5 and E9.5 (Gomez Perdiguero et al., 2015; 
Hoeffel et al., 2015). In contrast, the transcriptional program that drives the emergence of EMPs 
begins between E6.5-E7.5, the first EMPs emerge at E8.25, continue to arise until at least 
E10.5, and proliferate until birth (Chen et al., 2011; Tanaka et al., 2012; Tober et al., 2013). As 
such, our system labels only a minority of one subset of EMPs and it is possible that other HSC-
independent progenitors, including distinct EMP subpopulations and neonatal repopulating cells, 
may respond differently when expressing PTPN11 mutations (Yoder et al., 1997; Sheng et al., 
2015; Frame et al., 2016).  
In conclusion, we present the first study to evaluate the contribution of HSC-independent 
hematopoietic progenitors to JMML. We show that YS EMPs expressing gain-of-function 
PTPN11 are hypersensitive to GM-CSF and have hyperactive RAS-ERK signaling. 
Nevertheless, mutant EMPs were not able to give rise to disease upon transplantation nor in the 
context of unperturbed development. Our findings suggest YS EMPs may be resistant to 
transformation by this mutation. We conclude that PTPN11E76K expression in a subset of YS 
EMPs does not result in an expansion of mutant macrophages and is not sufficient for MPN 
emergence in a mouse model of JMML. 
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Experimental Procedures 
Mice 
C57BL/6J, B6.SJL-Ptprca Pepcb/ (BoyJ), and NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice 
were bred in-house. LSL-PTPN11D61Y/+ mice were obtained from Dr. Gordon Chan and Dr. 
Benjamin Neel (U. Toronto, Canada). LSL-PTPN11E76K/+ mice were obtained from Dr. Cheng-
Kui Qu (U. Emory, Atlanta, GA).  ROSAYFP/YFP mice were obtained from Dr. Anthony Firulli 
(IUSM, Indianapolis, IN). CSF1R-Mer-Cre-Mer mice (#019098) were purchased from Jackson 
Labs and were back-crossed onto the C57B6 background for 6 generations. VavCreCroker mice 
were mated with PTPN11E76K and were a gift from Dr. David Williams (Boston Children’s 
Hospital, Boston, MA). VavCredeBoer mice were mated with PTPN11D61Y and were a gift from Dr. 
Reuben Kapur (IUSM, Indianapolis, IN). Mice were identified by ear notches or toe clips. 
Genotyping was performed with conventional PCR using primers listed in the Appendix. 
Experimental and control animals were housed together in the same cages. All animal studies 
were performed with prior approval from the IUSM Institutional Animal Care and Use 
Committee. 
Mouse hematologic analysis 
Blood collections were done via tail vein into EDTA-coated tubes (Fisher #NC9628695). Counts 
were obtained using a HemaVet 950 (Drew Scientific). Blood smears and cytospins were 
stained using Modified Wright-Giemsa dyes on a Hematek 3000 system (Siemens). For 
subsequent flow cytometric analysis, up to 60ul of blood was aliquoted into 1ml of Blood 
Collection Medium (IMDM +10%FBS +1% Pen/Strep + 20U/ml Heparin (Sigma #H3149)). 
Timed Matings 
Male studs (10-26 weeks of age) were housed in separate cages and mated after at least 2-3 
days of acclimatization to their cage. In the evening one or two female mice (8-26 weeks of age) 
were moved to the stud cage. The following morning, successful matings were confirmed by 
visual inspection of a vaginal plug and assigned a gestational age of E0.5.  
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Tamoxifen Treatment 
To induce recombinase activity in utero, pregnant dams were injected i.p. with 75ug/g 4-hydroxy 
tamoxifen (Sigma #H6278) along with 37.5ug/g progesterone (Sigma #P0130). Litters of 
tamoxifen-treated dams were routinely delivered by C-section on E19.5 and raised by foster 
females. 
Embryo Harvests 
Pregnant females were euthanized by cervical dislocation followed by bilateral pneumothorax. 
The abdominal cavity was opened using sterile scissors and forceps. The uterine horns were 
removed and placed in a petri dish with sterile PBS. The uterine fascia, musculature, and 
placental tissues were sequentially removed using forceps to expose the YS-enclosed embryo. 
Embryo age was confirmed by counting somite pairs: E9.5 (20-26sp), E10.0 (27-32sp), E10.5 
(33-37sp). Desired tissues were dissected out and placed into collection tubes containing PBS. 
Tissue digests were performed for 5-30min at 37oC in 0.125% collagenase type I (Stem Cell 
Technologies #07902).  
Ex Vivo Culture 
Cells were cultured in a humidified incubator at 37ºC, 5% CO2 in IMDM (Fisher #12440079), 
10% FBS (Fisher #SH30070.03), 100 U/ml Penicillin/Streptomycin (Fisher #15140122), 440nM 
β-Mercaptoethanol (Sigma #M6250), and 2mM L-Glutamine (Fisher # 25030-081). Yolk sac or 
fetal liver cells were differentiated into macrophages by culturing for 7 days in 10ng/ml M-CSF 
(Peprotech #315-02). 
Hematopoietic Cell Isolations 
All tissues were kept on ice in PBS +2mM EDTA. Bone marrow cells were flushed from hindlimb 
bones. Spleens were triturated with glass cover slides. Livers, hearts, and brains were minced 
with razors and digested at 37ºC in 0.2% collagenase D (Sigma #11088866001), 0.5% Dispase 
(Fisher #17105-041) and 50U/ml DNase I (Sigma #10104159001) for 60min. Enucleated RBCs 
were depleted as necessary using density gradient centrifugation in Histopaque (Sigma #10771) 
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or RBC lysis buffer (Quiagen #158904). As needed, liver and brain suspensions were depleted 
of parenchymal cells and lipids via centrifugation through a 37% and 50% Percoll (Sigma 
#P1644) gradient, respectively. 
Flow Cytometry 
Cells were stained at a concentration of 1-5 x 107/ml in PBS +2% FBS + 2mM EDTA. Antibody 
concentrations were determined experimentally. If required, cells were fixed in 1% PFA (Fisher 
#50-980-487). For cell cycle analysis, stained cells were permeabilized with eBioscience 
Intracellular Fixation & Permeabilization Buffer Set (#88-8824-00). For Intracellular phospho-
flow, cells were stimulated in an Eppendorf tube with GM-CSF (Peprotech #315-03), fixed in 1% 
PFA for 15min, and permeabilized using BD Perm Buffer III (#558050). Stained cells were 
analyzed using the BD LSR Fortessa, BD FACS CANTO II, or BD Accuri C6. Post run analysis 
was performed using FlowJo (Treestar). 
Tissue Histopathology 
Tissue samples were fixed in 4% PFA, dehydrated with ethanol, cleared with xylenes and 
embedded in paraffin. 5um sections were cut on a rotary microtome and stained with 
hematoxylin and eosin. 
DNA isolation 
Murine tails were digested for 1hr at 95ºC in 50mM NaOH + 0.2mM EDTA, vortexed, pelleted, 
and then diluted to 100mM Tris buffer. Alternatively, DNA was isolated from tissues using the 
DNeasy Blood & Tissue Kit (Quiagen # 69504). 
Hematopoietic Progenitor Colony Forming Assay 
2x104 FL mononuclear cells, 2.5 x105 spleen cells or 1/5 of total YS cells were plated in 1ml of 
30% methylcellulose in IMDM (Stemcell Technologies #M3120) supplemented with 30% FBS, 
2.2% Pen/Strep, 2.45mM L-Glutamine, and 440nM β-Mercaptoethanol (Sigma #M6250) and 
defined concentration of murine GM-CSF. 
Transplantations 
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Adult recipients (8-24wks) were lethally irradiated with 700cGy+400cGy. Within 16hrs, donor 
cells were adoptively transferred via tail vein in 250ul PBS using a 28G insulin syringe (Fisher 
#BD 329461). A heat lamp and alcohol swab was used to engorge the vein.  Neonatal NSG 
recipients (2 day-old) were sublethally irradiated with 150cGy. Immediately after irradiation, 
donor cells were adoptively transferred via facial vein in 30ul PBS using a 30G needle and a 
0.1ml syringe (Hamilton #1710). 
Western blots 
Protein extracts were obtained by lysing cultured or primary cells for 30min on ice in 50mM 
HEPES, 150mM NaCl, 10% Glycerol, 1% Triton X100, 1.5mM MgCl2, 1mM EGTA, 100mM 
NaF, 10mM NaPP, along with a protease inhibitor cocktail containing sodium vanadate, ZnCl2, 
PMSF (Sigma # 93482), and enzymatic inhibitors (Sigma # 10837091001). Protein lysates were 
run using SDS-PAGE, transferred to nitrocellulose membranes. Blots were exposed using 
SuperSignal West Pico Chemiluminescent Substrate (Fisher #34080). 
Statistical analyses 
P-values were calculated using Graph Pad Prism 7.0. Two-tailed t-tests were used to compare 
two-variable experiments. Chi-squared analyses were used to compare birth ratios. Survival 
analyses were performed by Mantel-Cox log-rank tests. Two-way ANOVA analyses were used 
to compare changes in variables over time. All error bars represent SEM. P values <0.05 were 
considered significant. Notation: * p-value<0.05; ** p-value<0.01; *** p-value<0.001; ns not 
significant. 
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Figure Legends 
Figure 1. VavCre+;PTPN11D61Y E9.5 yolk sac EMPs have defining features of JMML. A) 
Genotype ratios at weaning of VavCre+ x PTPN11D61Y/+ matings; Chi-Squared p-value=0.04. B) 
Overall survival of VavCre+ x PTPN11D61Y/+ progeny (N=12 mutants, 53 littermates). C,D) 7 day 
methylcellulose colony formation of E14.5 FL cells (N=7 mutants, 7 controls) and E9.5 YS cells 
(N=11 mutants, 7 controls). E) Ex vivo FL-derived macrophages were stimulated for 30min with 
10ng/ml GM-CSF and lysates were probed with indicated antibodies. F) p-ERK and p-STAT5 
signaling in ex vivo cultures of E9.5 YS-derived macrophages following 30min of 5ng/ml GM-
CSF stimulation (N=5 biological replicates/group from 2 independent experiments). G) 
Methylcellulose assay with E9.5 YS sorted Ter119- cKit+ CD41dim EMPs (N=2 pooled litters). 
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Figure 2. VavCre+;PTPN11D61Y acquire T-ALL following healthy donor HSCT. A) Schematic 
of transplant. B) Donor engraftment in blood. C) Donor contribution to myeloid and lymphoid 
peripheral blood leukocytes. D) Overall survival of transplant recipients. E) Representative flow 
cytometry of CD45.2+ host-derived abnormal T-lymphocytes in the BM and spleen of mutant 
recipients. Immunohistochemistry of F) BM and G) spleen of mutant and littermate transplant 
recipients. 
Figure 3. VavCre+;PTPN11E76K YS EMPs engraft neonatal recipients but do not give rise 
to MPN. A) 7 day colony formation from sorted Ter119- cKit+ CD41dim E10.0 YS EMPs (n=4 
embryos/group from 2 litters). B) Methylcellulose colony formation by mutant and littermate YS 
progenitors (N=3 litters, analysis by Chi-Squared test). C) Genotype ratio of animals weaned 
from VavCre+ x PTPN11E76K/+ matings (N=45 births). D) Representative images of E10.0 and 
E17.5 mutant and littermate embryos. E-G) YS and AGM progenitors from E10.5 
VavCre+;PTPN11E76K embryos were transplanted into 2 day-old NSG neonatal recipients. E) 
Leukocyte counts of recipients (N=2 recipients/group). F) Representative gating of YS EMP-
derived splenic macrophages in neonatal recipients. G) YS EMPs from mutant embryos do not 
contribute to microglial populations in engrafted animals. 
Figure 4. Analysis of CSF1R-MCM+;ROSAYFP;PTPN11E76K E9.5 EMPs. A) Schematic of 
mating strategy and 4-hyroxy tamoxifen (4OHT) administration to pregnant dams. B) Frequency 
of EMPs in E9.5 YS. C) Proportion of EMPs that are YFP+ following E8.5 4OHT. D) Ki67 
expression in E9.5 YS EMPs (normalized to average median fluorescence intensity among 
EMPs in each litter). E) p-ERK expression among ex vivo E9.5 YS EMP-derived macrophages 
after stimulation with 20ng/ml (N=3 embryos/group). 
Figure 5. Peripheral blood analysis of CSF1R-MCM+;ROSAYFP;PTPN11E76K. A) Schematic of 
mating. All litters were born to dams who were injected with 4OHT at E8.5. B) Genotype ratios 
at weaning (N=14 mutants and 43 controls). C) CBC analysis of leukocyte frequency. D) 
Frequency of YFP+ leukocytes in peripheral blood. E) Frequency of myeloid and lymphoid 
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progeny in peripheral blood. F,G) Hemoglobin and platelet abundance in peripheral blood). H) 
Overall survival. 
Figure 6. Macrophage analysis in CSF1R-MCM+;ROSAYFP;PTPN11E76K animals. Analyses 
were performed 52-60 weeks after birth following in utero exposure to 4OHT at E8.5. A,B) 
Normalized weights of spleens and livers. C,D) Frequency of B-cells, T-cells, and myeloid cells 
in the bone marrow and spleen of mutants and littermates as measured by flow cytometry. E,F) 
Frequency of YFP+ macrophages (CD45+ CD11b+ F4/80+). G) 7 day methylcellulose colony 
formation from splenic progenitors cultured in in 10ng/ml GM-CSF. H) PCR analysis detects 
recombined LSL-PTPN11E76K locus in genomic DNA from mutant brain samples. Image is a 
concatenation of lanes run on a single gel. I) p-ERK expression in microglia following stimulation 
with 10ng/ml GM-CSF for indicated durations. (N=5 mutant and 12 controls). J) Representative 
p-ERK expression in freshly-harvested, unstimulated microglia. 
  
Page 22 of 35
John Wiley & Sons, Inc.
Developmental Dynamics
D
ev
el
op
m
en
ta
l D
yn
am
ic
s
REFERENCES 
Arora N, Wenzel PL, McKinney-Freeman SL, Ross SJ, Kim PG, Chou SS, Yoshimoto M, Yoder 
MC, Daley GQ. 2014. Effect of Developmental Stage of HSC and Recipient on Transplant 
Outcomes. Dev Cell 29:621-628. 
Bertrand JY, Jalil A, Klaine M, Jung S, Cumano A, Godin I. 2005. Three pathways to mature 
macrophages in the early mouse yolk sac. Blood 106:3004-3011. 
Boisset JC, van Cappellen W, Andrieu-Soler C, Galjart N, Dzierzak E, Robin C. 2010. In vivo 
imaging of haematopoietic cells emerging from the mouse aortic endothelium. Nature 
464:116-120. 
Bowie MB, Kent DG, Dykstra B, McKnight KD, McCaffrey L, Hoodless PA, Eaves CJ. 2007. 
Identification of a new intrinsically timed developmental checkpoint that reprograms key 
hematopoietic stem cell properties. Proc Natl Acad Sci U S A 104:5878-5882. 
Boyer SW, Schroeder AV, Smith-Berdan S, Forsberg EC. 2011. All hematopoietic cells develop 
from hematopoietic stem cells through Flk2/Flt3-positive progenitor cells. Cell Stem Cell 
9:64-73. 
Buchrieser J, James W, Moore MD. 2017. Human Induced Pluripotent Stem Cell-Derived 
Macrophages Share Ontogeny with MYB-Independent Tissue-Resident Macrophages. 
Stem Cell Reports 8:334-345. 
Busch K, Klapproth K, Barile M, Flossdorf M, Holland-Letz T, Schlenner SM, Reth M, Hofer T, 
Rodewald HR. 2015. Fundamental properties of unperturbed haematopoiesis from stem 
cells in vivo. Nature 518:542-546. 
Busch K, Rodewald HR. 2016. Unperturbed vs. post-transplantation hematopoiesis: both in vivo 
but different. Curr Opin Hematol 23:295-303. 
Caye A, Strullu M, Guidez F, Cassinat B, Gazal S, Fenneteau O, Lainey E, Nouri K, Nakhaei-
Rad S, Dvorsky R, Lachenaud J, Pereira S, Vivent J, Verger E, Vidaud D, Galambrun C, 
Picard C, Petit A, Contet A, Poiree M, Sirvent N, Mechinaud F, Adjaoud D, Paillard C, 
Nelken B, Reguerre Y, Bertrand Y, Haussinger D, Dalle JH, Ahmadian MR, Baruchel A, 
Chomienne C, Cave H. 2015. Juvenile myelomonocytic leukemia displays mutations in 
components of the RAS pathway and the PRC2 network. Nat Genet 47:1334-1340. 
Chan G, Kalaitzidis D, Usenko T, Kutok JL, Yang W, Mohi MG, Neel BG. 2009a. Leukemogenic 
Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple 
stages of hema. Blood 113:4414-4424. 
Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. 2009b. Juvenile myelomonocytic leukemia: a 
report from the 2nd International JMML Symposium. Leuk Res 33:355-362. 
Chan RJ, Yoder MC. 2013. JMML patient-derived iPSCs induce new hypotheses. Blood 
121:4815-4817. 
Chen MJ, Li Y, De Obaldia ME, Yang Q, Yzaguirre AD, Yamada-Inagawa T, Vink CS, 
Bhandoola A, Dzierzak E, Speck NA. 2011. Erythroid/myeloid progenitors and 
hematopoietic stem cells originate from distinct populations of endothelial cells. Cell Stem 
Cell 9:541-552. 
Christensen JL, Wright DE, Wagers AJ, Weissman IL. 2004. Circulation and chemotaxis of fetal 
hematopoietic stem cells. PLoS Biol 2:E75. 
Cooper LJ, Shannon KM, Loken MR, Weaver M, Stephens K, Sievers EL. 2000. Evidence that 
juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood 96:2310-
2313. 
Croker B, Metcalf D, Robb L, Wei W, Mifsud S, DiRago L, Cluse L, Sutherland K, Hartley L, 
Williams E, Zhang J-G, Hilton D, Nicola N, Alexander W. 2004. SOCS3 is a critical 
physiological negative regulator of G-CSF signaling and emergency granulopoiesis. 
Immunity 20:153-165. 
Page 23 of 35
John Wiley & Sons, Inc.
Developmental Dynamics
D
ev
el
op
m
en
ta
l D
yn
am
ic
s
de Boer J, Williams A, Skavdis G, Harker N, Coles M, Tolaini M, Norton T, Williams K, Roderick 
K, Potocnik AJ, Kioussis D. 2003. Transgenic mice with hematopoietic and lymphoid 
specific expression of Cre. European journal of immunology 33:314-325. 
DeFalco T, Bhattacharya I, Williams AV, Sams DM, Capel B. 2014. Yolk-sac-derived 
macrophages regulate fetal testis vascularization and morphogenesis. Proc Natl Acad Sci 
U S A:E2384-E2393. 
Dong L, Yu WM, Zheng H, Loh ML, Bunting ST, Pauly M, Huang G, Zhou M, Broxmeyer HE, 
Scadden DT, Qu CK. 2016. Leukaemogenic effects of Ptpn11 activating mutations in the 
stem cell microenvironment. Nature 539:304-308. 
Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, Brija T, Gautier EL, 
Ivanov S, Satpathy AT, Schilling JD, Schwendener R, Sergin I, Razani B, Forsberg EC, 
Yokoyama WM, Unanue ER, Colonna M, Randolph GJ, Mann DL. 2014. Embryonic and 
adult-derived resident cardiac macrophages are maintained through distinct mechanisms at 
steady state and during inflammation. Immunity 40:91-104. 
Espin-Palazon R, Stachura DL, Campbell CA, Garcia-Moreno D, Del Cid N, Kim AD, Candel S, 
Meseguer J, Mulero V, Traver D. 2014. Proinflammatory signaling regulates hematopoietic 
stem cell emergence. Cell 159:1070-1085. 
Frame JM, Fegan KH, Conway SJ, McGrath KE, Palis J. 2016. Definitive Hematopoiesis in the 
Yolk Sac Emerges from Wnt-Responsive Hemogenic Endothelium Independently of 
Circulation and Arterial Identity. Stem Cells 34:431-444. 
Frame JM, McGrath KE, Palis J. 2013. Erythro-myeloid progenitors: "definitive" hematopoiesis 
in the conceptus prior to the emergence of hematopoietic stem cells. Blood Cells Mol Dis 
51:220-225. 
Gandre-Babbe S, Paluru P, Aribeana C, Chou ST, Bresolin S, Lu L, Sullivan SK, Tasian SK, 
Weng J, Favre H, Choi JK, French DL, Loh ML, Weiss MJ. 2013. Patient-derived induced 
pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic 
leukemia. Blood 121:4925-4929. 
Ghiaur G, Ferkowicz MJ, Milsom MD, Bailey JL, Witte D, Cancelas JA, Yoder MC, Williams DA. 
2008. Rac1 is essential for intraembryonic hematopoiesis and for the initial seeding of fetal 
liver with definitive hem. Blood 111:3313-3321. 
Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, 
Stanley ER, Samokhvalov IM, Merad M. 2010. Fate mapping analysis reveals that adult 
microglia derive from primitive macrophages. Science 330:841-845. 
Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L, Garner H, Trouillet 
C, de Bruijn MF, Geissmann F, Rodewald HR. 2015. Tissue-resident macrophages 
originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518:547-551. 
Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, 
Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL. 2017. PD-1 expression by tumour-
associated macrophages inhibits phagocytosis and tumour immunity. Nature 545:495-499. 
Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, Spann NJ, Stender JD, 
Chun HB, Garner H, Geissmann F, Glass CK. 2014. Environment drives selection and 
function of enhancers controlling tissue-specific macrophage identities. Cell 159:1327-
1340. 
Haniffa M, Ginhoux F, Wang XN, Bigley V, Abel M, Dimmick I, Bullock S, Grisotto M, Booth T, 
Taub P, Hilkens C, Merad M, Collin M. 2009. Differential rates of replacement of human 
dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. J 
Exp Med 206:371-385. 
Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, Becker CD, See P, Price J, 
Lucas D, Greter M, Mortha A, Boyer SW, Forsberg EC, Tanaka M, van Rooijen N, Garcia-
Sastre A, Stanley ER, Ginhoux F, Frenette PS, Merad M. 2013. Tissue-resident 
Page 24 of 35
John Wiley & Sons, Inc.
Developmental Dynamics
D
ev
el
op
m
en
ta
l D
yn
am
ic
s
macrophages self-maintain locally throughout adult life with minimal contribution from 
circulating monocytes. Immunity 38:792-804. 
Helsmoortel HH, Bresolin S, Lammens T, Cave H, Noellke P, Caye A, Ghazavi F, de Vries A, 
Hasle H, Labarque V, Masetti R, Stary J, van den Heuvel-Eibrink MM, Philippe J, Van Roy 
N, Benoit Y, Speleman F, Niemeyer C, Flotho C, Basso G, Te Kronnie G, Van Vlierberghe 
P, De Moerloose B. 2016. LIN28B overexpression defines a novel fetal-like subgroup of 
juvenile myelomonocytic leukemia. Blood 127:1163-1172. 
Hoeffel G, Chen J, Lavin Y, Low D, Almeida FF, See P, Beaudin AE, Lum J, Low I, Forsberg 
EC, Poidinger M, Zolezzi F, Larbi A, Ng LG, Chan JK, Greter M, Becher B, Samokhvalov 
IM, Merad M, Ginhoux F. 2015. C-myb(+) erythro-myeloid progenitor-derived fetal 
monocytes give rise to adult tissue-resident macrophages. Immunity 42:665-678. 
Kasaai B, Caolo V, Peacock HM, Lehoux S, Gomez-Perdiguero E, Luttun A, Jones EA. 2017. 
Erythro-myeloid progenitors can differentiate from endothelial cells and modulate 
embryonic vascular remodeling. Sci Rep 7:43817. 
Kennedy DW, Abkowitz JL. 1997. Kinetics of central nervous system microglial and 
macrophage engraftment: analysis using a transgenic bone marrow transplantation model. 
Blood 90:986-993. 
Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG, Wieghofer P, Heinrich A, 
Riemke P, Holscher C, Muller DN, Luckow B, Brocker T, Debowski K, Fritz G, Opdenakker 
G, Diefenbach A, Biber K, Heikenwalder M, Geissmann F, Rosenbauer F, Prinz M. 2013. 
Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. 
Nat Neurosci 16:273-280. 
Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergstrasser E, Emanuel PD, Hasle H, 
Kardos G, Klein C, Kojima S, Stary J, Trebo M, Zecca M, Gelb BD, Tartaglia M, Loh ML. 
2005. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and 
Noonan syndrome/myeloproliferative disease. Blood 106:2183-2185. 
Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, Jung S, Amit I. 2014. 
Tissue-resident macrophage enhancer landscapes are shaped by the local 
microenvironment. Cell 159:1312-1326. 
Li Y, Esain V, Teng L, Xu J, Kwan W, Frost IM, Yzaguirre AD, Cai X, Cortes M, Maijenburg MW, 
Tober J, Dzierzak E, Orkin SH, Tan K, North TE, Speck NA. 2014. Inflammatory signaling 
regulates embryonic hematopoietic stem and progenitor cell production. Genes Dev 
28:2597-2612. 
Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. 2005. Developmental stage-
selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 
37:613-619. 
Lin Y, Yoder MC, Yoshimoto M. 2014. Lymphoid progenitor emergence in the murine embryo 
and yolk sac precedes stem cell detection. Stem Cells Dev 23:1168-1177. 
Liu X, Zheng H, Li X, Wang S, Meyerson HJ, Yang W, Neel BG, Qu CK. 2016. Gain-of-function 
mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA 
damage-induced malignancies. Proc Natl Acad Sci U S A 113:984-989. 
Locatelli F, Crotta A, Ruggeri A, Eapen M. 2013. Analysis of risk factors influencing outcomes 
after cord blood transplantation in children with juvenile myelomonocytic leukemia: a 
EUROCORD, EBMT, EWOG. Blood 122:2135-2141. 
Locatelli F, Niemeyer CM. 2015. How I treat juvenile myelomonocytic leukemia. Blood 
125:1083-1090. 
Locatelli F, Nöllke P, Zecca M, Korthof E, Lanino E, Peters C, Pession A, Kabisch H, Uderzo C, 
Bonfim CS, Bader P, Dilloo D, Stary J, Fischer A, Révész T, Führer M, Hasle H, Trebo M, 
van den Heuvel-Eibrink MM, Fenu S, Strahm B, Giorgiani G, Bonora MR, Duffner U, 
Niemeyer CM. 2005. Hematopoietic stem cell transplantation (HSCT) in children with 
Page 25 of 35
John Wiley & Sons, Inc.
Developmental Dynamics
D
ev
el
op
m
en
ta
l D
yn
am
ic
s
juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood 
105:410-419. 
Lux CT, Yoshimoto M, McGrath KE, Conway SJ, Palis J, Yoder MC. 2008. All primitive and 
definitive hematopoietic progenitor cells emerging before E10 in the mouse embryo are 
products of the yolk sac. Blood 111:3435-3438. 
Matsuda K, Sakashita K, Taira C, Tanaka-Yanagisawa M, Yanagisawa R, Shiohara M, 
Kanegane H, Hasegawa D, Kawasaki K, Endo M, Yajima S, Sasaki S, Kato K, Koike K, 
Kikuchi A, Ogawa A, Watanabe A, Sotomatsu M, Nonoyama S. 2010. Quantitative 
assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical 
course in patients with juvenile myelomonocytic leukaemia. Br J Haematol 148:593-599. 
McGrath KE, Frame JM, Fegan KH, Bowen JR, Conway SJ, Catherman SC, Kingsley PD, 
Koniski AD, Palis J. 2015. Distinct Sources of Hematopoietic Progenitors Emerge before 
HSCs and Provide Functional Blood Cells in the Mammalian Embryo. Cell Rep 11:1892-
1904. 
Moore MA, Metcalf D. 1969. Ontogeny of the Haemopoietic System Yolk Sac Origin of In Viuo 
and In Vitro Colony Forming Cells in the Developing Mouse Embryo. Br J Haematol 
18:279-296. 
Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, Miller TA, Pietryga DW, Scott 
WJJ, Potter SS. 1991. A functional c-myb gene is required for normal murine fetal hepatic 
hematopoiesis. Cell 65:677-689. 
Mulero-Navarro S, Sevilla A, Roman AC, Lee DF, D'Souza SL, Pardo S, Riess I, Su J, Cohen N, 
Schaniel C, Rodriguez NA, Baccarini A, Brown BD, Cave H, Caye A, Strullu M, Yalcin S, 
Park CY, Dhandapany PS, Yongchao G, Edelmann L, Bahieg S, Raynal P, Flex E, 
Tartaglia M, Moore KA, Lemischka IR, Gelb BD. 2015. Myeloid Dysregulation in a Human 
Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic 
Leukemia. Cell Rep 13:504-515. 
Muller AM, Medvinsky A, Strouboulis J, Grosveld F, Dzierzak E. 1994. Development of 
Hematopoietic in the Mouse Embryo Stem Cell Activity. Immunity 1:291-301. 
Olk-Batz C, Poetsch AR, Nollke P, Claus R, Zucknick M, Sandrock I, Witte T, Strahm B, Hasle 
H, Zecca M, Stary J, Bergstraesser E, De Moerloose B, Trebo M, van den Heuvel-Eibrink 
MM, Wojcik D, Locatelli F, Plass C, Niemeyer CM, Flotho C, European Working Group of 
Myelodysplastic Syndromes in C. 2011. Aberrant DNA methylation characterizes juvenile 
myelomonocytic leukemia with poor outcome. Blood 117:4871-4880. 
Palis J, Robertson S, Kennedy M, Wall C, Keller G. 1999. Development of erythroid and myeloid 
progenitors in the yolk sac and embryo proper of the mouse.pdf. Development 126:5073-
5084. 
Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. 
2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 
475:222-225. 
Rybtsov S, Sobiesiak M, Taoudi S, Souilhol C, Senserrich J, Liakhovitskaia A, Ivanovs A, 
Frampton J, Zhao S, Medvinsky A. 2011. Hierarchical organization and early hematopoietic 
specification of the developing HSC lineage in the AGM region. J Exp Med 208:1305-1315. 
Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, Shiraishi Y, Takahashi M, Kon A, Sanada M, 
Chiba K, Tanaka H, Makishima H, Wang X, Xu Y, Doisaki S, Hama A, Nakanishi K, 
Takahashi Y, Yoshida N, Maciejewski JP, Miyano S, Ogawa S, Kojima S. 2013. Exome 
sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile 
myelomonocytic leukemia. Nat Genet 45:937-941. 
Samokhvalov IM, Samokhvalova NI, Nishikawa S. 2007. Cell tracing shows the contribution of 
the yolk sac to adult haematopoiesis. Nature 446:1056-1061. 
Schlenner SM, Rodewald HR. 2010. Early T cell development and the pitfalls of potential. 
Trends Immunol 31:303-310. 
Page 26 of 35
John Wiley & Sons, Inc.
Developmental Dynamics
D
ev
el
op
m
en
ta
l D
yn
am
ic
s
Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, Prinz M, 
Wu B, Jacobsen SE, Pollard JW, Frampton J, Liu KJ, Geissmann F. 2012. A lineage of 
myeloid cells independent of Myb and hematopoietic stem cells. Science 336:86-90. 
Sheng J, Ruedl C, Karjalainen K. 2015. Fetal HSCs versus EMP2s. Immunity 43:1025. 
Stadtfeld M, Ye M, Graf T. 2007. Identification of interventricular septum precursor cells in the 
mouse embryo. Dev Biol 302:195-207. 
Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, 
Seepo S, Olsen SR, Rosenberg M, Archambeault SL, Abusin G, Beckman K, Brown PA, 
Briones M, Carcamo B, Cooper T, Dahl GV, Emanuel PD, Fluchel MN, Goyal RK, Hayashi 
RJ, Hitzler J, Hugge C, Liu YL, Messinger YH, Mahoney DH, Jr., Monteleone P, Nemecek 
ER, Roehrs PA, Schore RJ, Stine KC, Takemoto CM, Toretsky JA, Costello JF, Olshen AB, 
Stewart C, Li Y, Ma J, Gerbing RB, Alonzo TA, Getz G, Gruber TA, Golub TR, Stegmaier K, 
Loh ML. 2015. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet 
47:1326-1333. 
Tanaka Y, Hayashi M, Kubota Y, Nagai H, Sheng G, Nishikawa S, Samokhvalov IM. 2012. Early 
ontogenic origin of the hematopoietic stem cell lineage. Proc Natl Acad Sci U S A 
109:4515-4520. 
Tober J, Koniski A, McGrath KE, Vemishetti R, Emerson R, de Mesy-Bentley KK, Waugh R, 
Palis J. 2007. The megakaryocyte lineage originates from hemangioblast precursors and is 
an integral component both of primitive and of definitive hematopoiesis. Blood 109:1433-
1441. 
Tober J, Yzaguirre AD, Piwarzyk E, Speck NA. 2013. Distinct temporal requirements for Runx1 
in hematopoietic progenitors and stem cells. Development 140:3765-3776. 
Vanhee S, De Mulder K, Van Caeneghem Y, Verstichel G, Van Roy N, Menten B, Velghe I, 
Philippe J, De Bleser D, Lambrecht BN, Taghon T, Leclercq G, Kerre T, Vandekerckhove 
B. 2015. In vitro human embryonic stem cell hematopoiesis mimics MYB-independent yolk 
sac hematopoiesis. Haematologica 100:157-166. 
Weinberg RS, Leibowitz D, Weinblatt ME, Kochen J, Alter BP. 1990. Juvenile chronic 
myelogenous leukaemia: the only example of truly fetal (not fetal-like) erythropoiesis. Br J 
Haematol 76:307-310. 
Xu D, Liu X, Yu WM, Meyerson HJ, Guo C, Gerson SL, Qu CK. 2011. Non-lineage/stage-
restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on 
malignant transformation of hematopoietic cells. J Exp Med 208:1977-1988. 
Xu D, Zheng H, Yu WM, Qu CK. 2013. Activating mutations in protein tyrosine phosphatase 
Ptpn11 (Shp2) enhance reactive oxygen species production that contributes to 
myeloproliferative disorder. PLoS One 8:e63152. 
Yoder MC, Hiatt K. 1997. Engraftment of Embryonic Hematopoietic Cells in Conditioned 
Newborn Recipients. Blood 89:2176-2183. 
Yoder MC, Hiatt K, Dutt P, Mukherjee P, Bodine DM, Orlic D. 1997. Characterization of 
definitive lymphohematopoietic stem cells in the day 9 murine yolk sac. Immunity 7:335-
344. 
Yoshimoto M, Montecino-Rodriguez E, Ferkowicz MJ, Porayette P, Shelley WC, Conway SJ, 
Dorshkind K, Yoder MC. 2010. Embryonic day 9 yolk sac and intra-embryonic hemogenic 
endothelium independently generate a B-1 and marginal zone progenitor lacking B-2 
potential. Proc Natl Acad Sci U S A 108:1468-1473. 
Yoshimoto M, Porayette P, Glosson NL, Conway SJ, Carlesso N, Cardoso AA, Kaplan MH, 
Yoder MC. 2012. Autonomous murine T-cell progenitor production in the extra-embryonic 
yolk sac before HSC emergence. Blood 119:5706-5714. 
 
Page 27 of 35
John Wiley & Sons, Inc.
Developmental Dynamics
D
ev
el
op
m
en
ta
l D
yn
am
ic
s
Manufacturer Catalog 
number 
Antibody Clone 
eBioscience 45-0454-82 Anti-MouseCD45.2PerCP-Cyanine5.5 104 
BioLegend 109830 PE/Cy7anti-mouseCD45.2vAntibody 104 
BioLegend 109814 APCanti-mouseCD45.2 Antibody 104 
BioLegend 138006 Alexa Fluor® 647 anti-mouse CD144 (VE-cadherin) Antibody BV13 
eBioscience 17-0031-82 Anti-MouseCD3eAPC 145-2C11 
BioLegend 100306 FITC anti-mouse CD3ε Antibody 145-2C11 
BioLegend 133906 PE anti-mouse CD41 Antibody MWReg30 
BioLegend 105814 PE/Cy7anti-mouseCD117(c-Kit) Antibody 2B8 
BioLegend 100712 APC anti-mouse CD8a Antibody 53-6.7 
BioLegend 116212 APC anti-mouse TER-119/Erythroid Cells Antibody TER119 
eBioscience 47-0453-82 Anti-MouseCD45.1APC-eFluor®780 A20 
BioLegend 110714 APC anti-mouse CD45.1 Antibody A20 
BioLegend 116228 PerCP/Cy5.5 anti-mouse TER-119/Erythroid Cells Antibody TER119 
BioLegend 100443 BrilliantViolet421™anti-mouseCD4 Antibody GK1.5 
BioLegend 100413 APC/Cy7anti-mouseCD4 Antibody GK1.5 
BioLegend 123116 APC anti-mouse F4/80 Antibody BM8 
BioLegend 101208 PE anti-mouse/human CD11b Antibody M1/70 
BioLegend 101224 PacificBlue™anti-mouse/humanCD11b Antibody M1/70 
BioLegend 101212 APCanti-mouse/humanCD11b Antibody M1/70 
BioLegend 103208 PE anti-mouse/human CD45R/B220 Antibody RA3-6B2 
eBioscience 25-0452-82 Anti-Human/MouseCD45R(B220)PE-Cyanine7 RA3-6B2 
BioLegend 103206 FITC anti-mouse/human CD45R/B220 Antibody RA3-6B2 
BDBiosciences 51-01212J BiotinRatanti-MouseLy-6GandLy-6C RB6-8C5 
Biolegend 108427 PerCP/Cy5.5anti-mouseLy-6G/Ly-6C(Gr-1) Antibody RB6-8C5 
Biolegend 652423 PerCP/Cy5.5 anti-mouse Ki-67 Antibody 16A8 
Biolegend 423103 ZombieYellow™ Fixable Viability Kit  
Cell Signaling Technologies 9101S Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)  
Cell Signaling Technologies 9365S Phospho-Stat5 (Tyr694) (C71E5) Rabbit mAb  
Cell Signaling Technologies 4414S Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor® 647)  
Cell Signaling Technologies 4695S p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb  
Table 1. List of antibodies. 
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CSF1R Mer-Cre-Mer and VavCredeBoer  
CTAGGCCACAGAATTGAAAGATCT  
GTAGGTGGAAATTCTAGCATCATCC  
AGATGCCAGGACATCAGGAACCTG  
ATCAGCCACACCAGACACAGAGATC 
 
VavCreCroker 
 CTTCTAGGCCTGTACGGAAGTGTT 
CGCGCGCCTGAAGATATAGAAGAT 
 
PTPN11 D61Y 
 CCTGAATGAACTGCAGGACG 
GTTTCGCTTGGTGGTCGAAT 
 
PTPN11 E76K – Genomic 
 TGGGAAGACAATAGCAGGCA  
CCCACTCACCTTGTCATGTA 
 
PTPN11 E76K – Recombined 
 GGGAATTGAACTCAGGACCT  
CCCACTCACCTTGTCATGTA 
 
ROSA YFP 
 AAGACCGCGAAGAGTTTGTC 
AAAGTCGCTCTGAGTTGTTAT 
GGAGCGGGAGAAATGGATATG 
 
2.List of primers used for genotyping. 
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Figure 1. VavCre+;PTPN11D61Y E9.5 yolk sac EMPs have defining features of JMML. A) Genotype 
ratios at weaning of VavCre+ x PTPN11D61Y/+ matings; Chi-Squared p-value=0.04. B) Overall survival of 
VavCre+ x PTPN11D61Y/+ progeny (N=12 mutants, 53 littermates). C,D) 7 day methylcellulose colony 
formation of E14.5 FL cells (N=7 mutants, 7 controls) and E9.5 YS cells (N=11 mutants, 7 controls). E) Ex 
vivo FL-derived macrophages were stimulated for 30min with 10ng/ml GM-CSF and lysates were probed 
with indicated antibodies. F) p-ERK and p-STAT5 signaling in ex vivo cultures of E9.5 YS-derived 
macrophages following 30min of 5ng/ml GM-CSF stimulation (N=5 biological replicates/group from 2 
independent experiments). G) Methylcellulose assay with E9.5 YS sorted Ter119- cKit+ CD41dim EMPs (N=2 
pooled litters).  
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Figure 2. VavCre+;PTPN11D61Y acquire T-ALL following healthy donor HSCT. A) Schematic of 
transplant. B) Donor engraftment in blood. C) Donor contribution to myeloid and lymphoid peripheral blood 
leukocytes. D) Overall survival of transplant recipients. E) Representative flow cytometry of CD45.2+ host-
derived abnormal T-lymphocytes in the BM and spleen of mutant recipients. Immunohistochemistry of F) BM 
and G) spleen of mutant and littermate transplant recipients.  
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Figure 3. VavCre+;PTPN11E76K YS EMPs engraft neonatal recipients but do not give rise to MPN. A) 
7 day colony formation from sorted Ter119- cKit+ CD41dim E10.0 YS EMPs (n=4 embryos/group from 2 
litters). B) Methylcellulose colony formation by mutant and littermate YS progenitors (N=3 litters, analysis 
by Chi-Squared test). C) Genotype ratio of animals weaned from VavCre+ x PTPN11E76K/+ matings (N=45 
births). D) Representative images of E10.0 and E17.5 mutant and littermate embryos. E-G) YS and AGM 
progenitors from E10.5 VavCre+;PTPN11E76K embryos were transplanted into 2 day-old NSG neonatal 
recipients. E) Leukocyte counts of recipients (N=2 recipients/group). F) Representative gating of YS EMP-
derived splenic macrophages in neonatal recipients. G) YS EMPs from mutant embryos do not contribute to 
microglial populations in engrafted animals.  
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Figure 4. Analysis of CSF1R-MCM+;ROSAYFP;PTPN11E76K E9.5 EMPs. A) Schematic of mating strategy 
and 4-hydroxy tamoxifen (4OHT) administration to pregnant dams. B) Frequency of EMPs in E9.5 YS. C) 
Proportion of EMPs that are YFP+ following E8.5 4-OHT. D) Ki67 expression in E9.5 YS EMPs (normalized to 
average median fluorescence intensity among EMPs in each litter). E) p-ERK expression among ex vivo E9.5 
YS EMP-derived macrophages after stimulation with 20ng/ml (N=3 embryos/group).  
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Figure 5. Peripheral blood analysis of CSF1R-MCM+;ROSAYFP;PTPN11E76K. A) Schematic of mating. All 
litters were born to dams who were injected with 4OHT at E8.5. B) Genotype ratios at weaning (N=14 
mutants and 43 controls). C) CBC analysis of leukocyte frequency. D) Frequency of YFP+ leukocytes in 
peripheral blood. E) Frequency of myeloid and lymphoid progeny in peripheral blood. F,G) Hemoglobin and 
platelet abundance in peripheral blood). H) Overall survival.  
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Figure 6. Macrophage analysis in CSF1R-MCM+;ROSAYFP;PTPN11E76K animals. Analyses were 
performed 52-60 weeks after birth following in utero exposure to 4OHT at E8.5. A,B) Normalized weights of 
spleens and livers. C,D) Frequency of B-cells, T-cells, and myeloid cells in the bone marrow and spleen of 
mutants and littermates as measured by flow cytometry. E,F) Frequency of YFP+ macrophages (CD45+ 
CD11b+ F4/80+). G) 7 day methylcellulose colony formation from splenic progenitors cultured in in 10ng/ml 
GM-CSF. H) PCR analysis detects recombined LSL-PTPN11E76K locus in genomic DNA from mutant brain 
samples. Image is a concatenation of lanes run on a single gel. I) p-ERK expression in microglia following 
stimulation with 10ng/ml GM-CSF for indicated durations. (N=5 mutant and 12 controls). J) Representative 
p-ERK expression in freshly-harvested, unstimulated microglia.  
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